ChemoCentryx Soars 337% After Announcing Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis with VFMCRP

“We are delighted with the positive topline data from the Phase III ADVOCATE trial for the treatment of ANCA vasculitis,” — Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks —   — Significantly reduced […]

Canopy Growth Expands Investor Relations Team with Appointment of Wall Street Equity Research Veteran Judy Hong as Vice President, Investor Relations

“We are very pleased to have a capital markets professional with Judy’s experience join our investor relations team,” said Mike Lee, Executive Vice President and Chief Financial Officer. “We believe Judy’s extensive knowledge of the consumer products goods sector, along with her credibility among key institutional investors, will help Canopy expand […]

FDA Warns 15 Companies for Illegally Selling Various Products Containing Cannabidiol (CBD) as Agency Details Safety Concerns

For Immediate Release:November 25, 2019 Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA also published a revised Consumer Update detailing safety concerns about CBD products […]

Top 3 Biotech/Pharma Breakout Stocks

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 94.4%) Sorrento Therapeutics (NASDAQ: SRNE) closed up 94.4% at $3.11 on NASDAQ with record volume of 75.02 million shared traded. The company reported that they rejected an offer to be acquired by two pharmaceutical companies for between $3.00 and $5.00 per share in cash. JanOne […]

JanOne Soars 55% Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD)

Phase 2b testing planned for PAD treatment and PAD-associated pain to address 8.5 million patient US market LAS VEGAS, Nov. 25, 2019 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, […]

GrowGeneration Corp. Approved to Begin Trading on NASDAQ Stock Exchange

DENVER, Nov. 25, 2019 /PRNewswire/ – GrowGeneration Corp. (NASDAQ: GRWG), (“GrowGen” or the “Company”) the largest chain of specialty retail hydroponic and organic garden centers, with currently 25 locations, is pleased to announce that its common shares have been approved for listing on the Nasdaq Capital Market (“NASDAQ”). GrowGeneration Corp. common shares will begin trading […]

Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal, Stock Price Soars 30% Pre- Market

November 25, 2019 07:00 ET | Source: Sorrento Therapeutics, SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the “Company”), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of the issued and […]

EyeGate Pharma Surges 48% Hitting Primary Endpoint in PRK Pivotal Study

WALTHAM, MA / ACCESSWIRE / November 22, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received select topline data, specifically the primary endpoint, demonstrating superiority over standard-of-care in its corneal wound […]

ASLAN Pharmaceuticals Surges 293% After Announcing Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical data characterising ASLAN003 as a potential treatment for acute myeloid leukaemia (AML) has been published in the November issue of Haematologica Journal. The findings support ASLAN003’s potential as […]

%d bloggers like this: